

ANALYTICA LTD | ABN 12 006 464 866

23 July 2015

ASX ANNOUNCEMENT

ENTITLEMENT OFFER – DESPATCH OF PROSPECTUS AND ENTITLEMENT & ACCEPTANCE FORM

BRISBANE, Australia – Analytica (ASX: ALT) advises that the Entitlement Offer Booklet and Entitlement & Acceptance Form relating to its partially underwritten renounceable rights issue announced on 8 July 2015, was despatched to eligible shareholders today.

Bryan Dulhunty

Company Secretary

Follow us on:









About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark clearance. Product launches are anticipated in Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.